[Experience in the treatment of iron deficiency anemia with ferro-folgamma].
The efficiency of therapy with the iron-containing preparation Ferro-Folgamma (Vervag Pharma, Germany) was evaluated in 62 men and women aged from 18 to 82 years with iron-deficiency anemia. Criteria for the efficiency were changes in clinical symptoms of anemia, hemoglobin level, erythrocyte and reticulocyte counts, packed cell volume, erythrocyte indices (mean erythrocyte volume, average content and concentration of hemoglobin in erythrocytes), erythropoietin level, and characteristics of iron metabolism (serum iron and ferritin levels, total iron-binding capacity of the serum, coefficient of ferritin saturation with iron), and drug tolerance. It was shown that Ferro-Folgamma is fairly well tolerated by the patients and produces good therapeutic effect when used to treat and prevent iron-deficiency anemia. Also, the study demonstrated that blood erythropoietin level being a sensitive indicator of hypoxia, it may be used as one of the most important criteria for the assessment of treatment efficiency in patients with iron-deficiency anemia.
Nikitin
E N
EN
Krasnoperova
O V
OV
Nikitin
Iu E
IuE
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018798:Anemia, Iron-Deficiency / Q000097:blood / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004921:Erythropoietin / Q000097:blood; D005260:Female; D005296:Ferrous Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D007501:Iron / Q000097:blood; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome; D055815:Young Adult
D005296:Ferrous Compounds; D006454:Hemoglobins; D004921:Erythropoietin; C020748:ferrous sulfate; D007501:Iron